The American Journal of Medicine
Volume 122, Issue 2, Supplement , Pages S14-S21 , February 2009

Efficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal Osteoporosis

  • John P. Bilezikian, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to John P. Bilezikian, MD, Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, New York 10032

References 

  1. National Osteoporosis Foundation. Fast Facts on Osteoporosis [fact sheet]. http://www.nof.org/osteoporosis/diseasefacts.htmAccessed July 15, 2008
  2. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761–1767
  3. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int. 2005;16:229–238
  4. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465–475
  5. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008;http://www.nof.org/professionals/NOF_Clinicians_Guide.pdfAccessed March 25, 2008
  6. WHO Study Group on Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis: Report of a WHO Study Group. Geneva, Switzerland: World Health Organization; 1994;WHO Technical Report Series No. 843
  7. Kanis JA WHO Scientific Group. Assessment of Osteoporosis at the Primary Health-Care Level. [technical report] Sheffield, United Kingdom: World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield; 2007;
  8. FRAX (WHO Fracture Risk Assessment Tool). Sheffield, United Kingdom: World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield. http://www.shef.ac.uk/FRAXAccessed November 10, 2008
  9. Chapurlat RD, Delmas PD. Drug insight: bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab. 2006;2:211–219
  10. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures (Fracture Intervention Trial Research Group). Lancet. 1996;348:1535–1541
  11. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077–2082
  12. Black DM, Schwartz AV, Ensrud KE, et al. FLEX Research Group Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX) (A randomized trial). JAMA. 2006;296:2927–2938
  13. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano). 2000;12:1–12
  14. Rizzoli R The Alendronate Once-Weekly Study Group. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res. 2002;17:1988–1996
  15. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282:1344–1352
  16. Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11:83–91
  17. Sörensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone. 2003;32:120–126
  18. Mellström DD, Sörensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;75:462–468
  19. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344:333–340
  20. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 2002;71:103–111
  21. Harris ST, Watts NB, Li Z, Chines AA, Hanley DA, Brown JP. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin. 2004;20:757–764
  22. Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone. 2008;42:36–42
  23. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241–1249
  24. Reginster J-Y, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006;65:654–661
  25. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the Dosing Intravenous Administration Study. Arthritis Rheum. 2006;54:1838–1846
  26. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–1822
  27. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–1809

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(08)01191-1

doi: 10.1016/j.amjmed.2008.12.003

The American Journal of Medicine
Volume 122, Issue 2, Supplement , Pages S14-S21 , February 2009

Article Tools

* Image Usage & Resolution